Minhua Chu, Managing Partner at Transition Value Partner, shared a post on X:
‘RemeGen announced that its antibody-drug conjugate (ADC) disitamab vedotin (RC48) has received NMPA approval in China for a new indication.
The approval covers adult patients with unresectable or metastatic HER2‑low breast cancer (IHC 1+ or IHC 2+/ISH−) with liver metastases, who have received at least one prior systemic therapy in the metastatic setting, or who relapsed during or within 12 months after adjuvant chemotherapy.
This marks the fourth approved indication for disitamab vedotin in China, following approvals in gastric cancer, urothelial carcinoma, and HER2‑positive advanced breast cancer with liver metastases.”
Othet articles featuring Minhua Chu on OncoDaily.